Changes in the clinical features,treatments,and outcomes of patients with systemic light chain(AL)amyloidosis in Western China,2010-2022:A multicenter,retrospective,real-world study  

作　　者：Hongbin Yu Lei Zhao Jiawei Li Chunlan Zhang Qinyu Liu Jie Zhou Fang Xu Jian Xiao Ying Yuan Siyu Yan Yucheng Chen Qing Zhang Huifang Shang Zhangxue Hu Yu Wu 

机构地区：[1]Department of Hematology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [2]West China School of Public Health and West China Fourth Hospital,Sichuan University,Chengdu,Sichuan 610041,China [3]Department of Hematology,People’s Hospital of Deyang City,Deyang,Sichuan 618099,China [4]Department of Hematology,Mianyang Central Hospital,School of Medicine,University of Electronic Science and Technology of China,Mianyang,Sichuan 621099,China [5]Department of Hematology,Zigong First People’s Hospital,Zigong,Sichuan 643000,China [6]Department of Hematology,Guangyuan Central Hospital,Guangyuan,Sichuan 628099,China [7]Department of Cardiology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [8]Department of Neurology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [9]Department of Nephrology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China

出　　处：《Chinese Medical Journal》2024年第21期2624-2626,共3页中华医学杂志(英文版)

摘　　要：To the Editor:Systemic light chain(AL)amyloidosis,a rare and deadly disease affecting approximately 10 individuals per million each year worldwide,is marked by misfolded,aggregated immunoglobulin light chains produced by dangerous plasma cell or B cell clones.Diagnosis of AL amyloidosis often faces obstacles due to non-specific symptoms.

关 键 词：AMYLOID PATIENTS clinical 

分 类 号：R59[医药卫生—内科学]